

PEDIATRIC ONCOLOGY OUTREACH TO HUNGARY (POOH)

EUR #0037-G-00-1078-06
QUARTERLY PROGRAM PERFORMANCE REPORT
YEAR 4, 1995
3rd QUARTER

Participating Institutions:

University of Kansas Medical Center (KUMC)
National Institute of Neurosurgery (NINS)
Second Department of Pediatrics of the Semmelweis University
Medical School (SDP)

Month/Year: July, 1995

Component Description:

- A. Dr. Hedvig Bodanszky, SDP, will visit KUMC to work with Dr. Paul Schloerb, Department of Surgery.
- B. Follow-up of pediatric malignancies and data entry into the POOH Tumor Registry will continue.

Additions to the Implementation Plan:

- C. Dr. Joseph Borsi and Dr. Csilla Csaki will travel to KUMC to meet with Dr. Tribhawan Vats, Pediatric Hematology/Oncology, KUMC.
- D. Investigation into the purchase of equipment continues.

Narratives/Justification:

- A. Due to personal reasons, Dr. Hedvig Bodanszky postponed her visit to KUMC until October, 1995.
- B. Dr. Enikö Apjok, Data Manager at SDP, continued to enter data into the POOH tumor Registry. Dr. Apjok also acted as contact person for the 10 hospitals listed in the 2nd Quarter Report of the 4th Annual Winnie-the-POOH Symposium on Pediatric Malignancies held in May, 1995.
- C. Dr. Joseph Borsi, Chief of Pediatric Oncology at SDP and Dr. Csilla Csaki, Pediatrician at SDP traveled to KUMC to meet with Dr. Tribhawan Vats regarding the upgrade of treatment protocols at SDP. Dr. Borsi also delivered a Residents' Conference Lecture entitled "Use of Human Recombinant Erythropoietin for the Prevention and Treatment of Cytostatic Induced Anemia in Children."

Expenditures per Component:

B. Dr. Joseph Borsi	airfare.	1722.66
	per diem	280.00
	lodging.	<u>166.35</u>
	Total.	2169.01
Dr. Csilla Csaki	airfare.	1722.66
	per diem	280.00
	lodging.	<u>166.35</u>
	Total.	2169.01

<u>Status:</u>	<u>Complete</u>	<u>Incomplete</u>	<u>In Process</u>
	C	A	B,D

Month/Year: August, 1995

Component Description:

- A. A Hungarian Nurse Clinician will visit KUMC to plan the growth of a Pediatric Nurses' Association and Newsletter.
- B. Follow-up of pediatric malignancies and data entry into the POOH Tumor Registry will continue.

Additions to the Implementation Plan:

- C. The New York Academy of Sciences will respond to the application for sponsorship of the 1996 POOH annual medical symposium.

Narrative/Justification:

- A. It was decided that the issues of the Pediatric Nurses' Association and Newsletter could be dealt with in September when the Nurses' Training Course was to be held. Dr. Tribhawan Vats and Ms Lavonne Ridder, Pediatric Nurse Oncology Clinician would be in Hungary then. No Hungarian nurse came to KUMC in August.
- B. Dr. Robert Bolinger and Dr. Enikö Apjok conversed with each other during the month of August to work out questions raised by a Polish hospital implementing the POOH Pediatric Tumor Registry. Dr. Bolinger and Dr. Apjok will continue to collaborate in implementing the registry in Eastern Europe.
- C. The New York Academy of Sciences (NYAS) approved an application to sponsor the 1996, POOH Symposium on pediatric malignancies entitled "Challenges and Opportunities in Pediatric Oncology". (Application is appended as A.)

Expenditures per Component:

None

<u>Status:</u>	<u>Complete</u>	<u>Incomplete</u>	<u>In Process</u>
	C	A	B

Month/Year: September, 1995

Component Description:

- A. Dr. Tribhawan Vats, Co-Investigator, KUMC, will visit SDP and NINS to observe the effects of protocol upgrades and nursing training.
- B. A Quarterly Program Performance and Financial report will be submitted to USAID and the JCAHO.
- C. Follow-up of pediatric malignancies and data entry into the POOH Tumor Registry will continue.

Additions to the Implementation Plan:

- D. Investigation and purchase of equipment and materials for NINS and SDP will continue.

Narrative/Justification:

- A. Dr. Tribhawan Vats, Co-Investigator, KUMC as well as, Ms Lavonne Ridder, Pediatric Nurse Oncology Clinician, KUMC, traveled to Budapest to participate in a Nurses' Training program at SDP. (A report of the course is appended as B.) Dr. Vats also met with Dr. Joseph Borsi, Chief of Pediatric Oncology at SDP and Dr. István Nyáry, Director of NINS to discuss upgrades in current treatment protocols.
- B. This satisfies USAID requirements for a quarterly program report.
- C. Dr. Enikö Apjok continued to enter Hungarian data into the Pediatric Tumor Registry and Dr. Robert Bolinger continued to find tune the POOH Tumor Registry program to meet the needs of the East European hospitals using the program.
- D. A bidding process was initiated to purchase a pediatric gastroscope in accordance to State of Kansas regulations.

Expenditures per Component:

A.	Dr. Tribhawan Vats	airfare.	1490.45
		per diem	260.51
		lodging.	<u>513.00</u>
		TOTAL.	2263.96
	Ms Lavonne Ridder	airfare.	1233.32
		per diem	897.78
		lodging.	<u>347.05</u>
		TOTAL.	2478.15

<u>Status:</u>	<u>Complete</u>	<u>Incomplete</u>	<u>In Process</u>
	A,B		C,D

PEDIATRIC ONCOLOGY OUTREACH TO HUNGARY (POOH)
 QUARTERLY FINANCIAL REPORT
 3rd QUARTER, 1995
 July - September

	Cumulative Expenses to Prior Period 10/1/94- 06/30/95	Actual Expense This Period 07/01/95- 09/30/95	Cumulative Actual Expense to Date 10/01/91- 09/30/95
Personnel	722,451.97	27,044.53	749,496.50
Supplies/Equip	380,047.70	325.07	380,372.77
Travel	282,362.83	1,240.00	283,602.83
Other	286,711.47	3,107.07	289,818.54
Indirect Costs	444,509.95	2,537.34	447,047.29
TOTALS	2,116,083.92	34,254.01	2,150,337.93

The University of Kansas Medical Center

University of Kansas Cancer Center
Pediatric Oncology Outreach to Hungary

18 May, 1995

Conference Director
The New York Academy of Sciences
2 East 63rd Street
New York, New York 10021

Dear Sir,

Answering your Call for Proposals-CONFERENCES, I am pleased to submit a request for New York Academy of Sciences sponsorship of the Fifth Annual Pediatric Oncology Outreach to Hungary (POOH) conference to be held in Budapest, Hungary, in October 1996. This will be the final meeting of the USAID-funded partnership project between the Semmelweis University Second Department of Pediatrics and the National Institute of Neurosurgery in Budapest, Hungary, and the Cancer Center of the University of Kansas Medical Center in Kansas City. The language of the conference will be English. Since 1991 this \$2.5 million federal grant has provided technology and training to these two key Hungarian institutions which treat most Hungarian children with malignancies and brain tumors. Serendipity named the project for Winnie the Pooh and it has become a set-piece of US aid to Hungary, a country with an exceptionally able scientific and medical community still struggling to escape more than four decades of the stifling consequences of Soviet domination. The focus of the POOH project first widened in 1994 to include Hungary beyond Budapest and in 1995 and 1996 will expand to reach the other countries of Central and Eastern Europe.

Attached, is the outline of a three day pediatric oncology conference, Challenges and Opportunities in Pediatric Oncology, which will address all aspects of childhood malignancy from basic science research to clinical trials to supportive care. As you will note, speakers are from among world leaders in oncology. We will condense this list of topics and speakers to 30, presented in two half day sessions for each of three days. We mean to address most clinical and basic science areas of importance in childhood malignancy. The conference will be truly multidisciplinary with speakers and audience from the basic biological and medical sciences, neurosurgery, neurology, pediatrics, pediatric surgery, pathology, neuropathology, diagnostic radiology, and radiotherapy. The Hungarian principals, Professor Dezső Schuler and Professor István Nyáry, and the American

principals, Dr. John J. Kepes and Dr. Trihawan Vats, are sufficiently well-connected to guarantee that we will secure the speakers and the audience we seek. We are considering a poster session concurrent with the conference that would reflect pediatric oncology practice and research in Central and Eastern European countries. This meeting will be juxtaposed to the Societe Internationale d'Oncologie Pediatrique (SIOP) annual meeting in Vienna, just three hours from Budapest. SIOP, the world's largest pediatric oncology organization, will hold its annual meeting on 2 through 5 October, 1996. The POOH symposium will be scheduled on 7 through 9 October, 1996.

In addition to our POOH grant office in Kansas City, we have related offices and staff at the National Institut. for Neurosurgery and the Semmelweis Second Department of Pediatrics in Budapest. These three offices have cooperated to run this grant for the past three and one-half years and have already managed three small conferences; a fourth will be presented in Kecskemét, Hungary, in May 1995. From grant funds and returned overhead funds from the University of Kansas, we have \$100,000 budgeted for this October 1996 conference and another \$100,000 to provide travel grants to scientists and physicians from Central and Eastern European countries so they may attend this conference. We expect about 100 conference attendees from Hungary and another 100 from the surrounding countries of Albania, Bulgaria, Croatia, the Czech Republic, Poland, Romania, Serbia, Slovakia, and Ukraine. We are planning on a conference attendance of 250 and presume that interested pediatric oncologists and other physicians and scientists from Austria, Germany, and other European countries will attend.

Though we have a reasonable source of funds to conduct a good three day meeting in Budapest, we anticipate approaching pharmaceutical and medical supply companies, particularly in Europe, for additional assistance. There is, of course, also the possibility of charging a registration fee for those of the attendees who can afford to pay it. Once again, our principal aim is to get as many conference attendees from Central and Eastern European countries as possible. As you can imagine, there is great need to disseminate information about modern methods of diagnosis and treatment of childhood malignancy in Central and Eastern European countries, especially those which endured decades of repression in the orbit of the former Soviet Union.

Thus, we offer to the New York Academy of Sciences the chance to sponsor a scientific conference in Budapest, Hungary, in October 1996, that will present the basic and clinical aspects of pediatric oncology to a largely Central and Eastern European audience by world leaders in this field. It would seem likely to us that you would welcome exposure to the scientific community of this part of the world. We presume that you would wish to promote your academy through this meeting. We seek three things from the New York Academy of Sciences: the sponsorship and the cachet of your distinguished academy, publication as an Annals volume of the proceedings of this conference, and your assistance, as you may wish to give it, in planning and presenting this conference. I have discussed our 1996 conference plans with your president, Dr. Henry Greenberg, several times this year.

We are proposing a program of 30 lectures, instead of the 24 you have suggested. When the program is finalized, there will be at least six junior investigators represented.

The POOH project, from its serendipitous beginning, has enjoyed a remarkable success. It has significantly reduced morbidity and mortality from cancer in children in Hungary since 1991. In a sense, on behalf of my colleagues, I am inviting the New York Academy of Sciences to join in the scientific conference that will take POOH from Hungary throughout Central and Eastern Europe at the end of this USAID-funded children's project.

Yours sincerely,

Frederick F. Holmes, M.D.
Principal Investigator
Pediatric Oncology Outreach to Hungary (POOH) project

cc: Henry Greenberg, M.D., President
New York Academy of Sciences

Ms. Julia Terry, Project Officer
Agency for International Development

Final Revision, 18 May, 1995
THE NEW YORK ACADEMY OF SCIENCES
CONFERENCE PROPOSAL

Today's date: 18 May, 1995

Conference title: Challenges and Opportunities in Pediatric Oncology

Names, titles, affiliations, addresses, and phone numbers of conference proponents:

Frederick F. Holmes, M.D.
Professor of Medicine
Investigator
Pediatric Oncology Outreach to Hungary
University of Kansas Medical Center
39th & Rainbow Blvd.
Kansas City, Kansas 66160
913-588-4732
FAX: 913-588-4736

Dezsö Schuler, M.D., Ph.D., F.R.C.P.
Director, National Institute of Principal
Pediatrics
President, Hungarian Pediatric
Oncology Section
Co-investigator
Pediatric Oncology Outreach to
Hungary
Second Department of Pediatrics,
Semmelweis University Medical School
Tuzolto u 7-9
1095 Budapest, Hungary
tel: 361-215-1985
FAX: 361-215-9969

Tribhawan S. Vats, M.D.
Chief, Pediatric Hematology/Oncology
Co-Investigator
Pediatric Oncology Outreach to Hungary
Kansas Medical Center
39th & Rainbow Blvd.
Kansas 66160
tel: 913-588-4732
FAX: 913-588-4736

John J. Kepes, M.D.
Professor Emeritus, Pathology
Co-Investigator
Pediatric Oncology Outreach to University of
University of Kansas Medical Center
Kansas City,
39th & Rainbow Blvd.
Kansas City, Kansas 66160
tel: 913-588-4732
FAX: 913-588-4736

István Nyáry, M.D., Ph.D.
Director, National Institute of Neurosurgery
Co-Investigator
Pediatric Oncology Outreach to Hungary
National Institute of Neurosurgery
Amerikai ut 57
1145 Budapest, Hungary
tel: 361-251-2999
FAX: 361-251-5678

Number of days: 3

Number of attendees expected: 250

How did you arrive at this number?

It is expected that approximately 100 conference attendees from Hungary and another 100 from the surrounding countries of Albania, Bulgaria, Croatia, the Czech Republic, Poland, Romania, Serbia, Slovakia, and Ukraine will come. We are planning on a total conference attendance of 250 and presume that interested pediatric oncologists and other physicians and scientists from Austria, Germany, and other European countries will attend.

From what field of science do you think conference attendees will come?

Professionals involved in research related to childhood malignancy and clinicians who treat children will attend. They will include, molecular biologists, immunologists, geneticists, neurosurgeons, neurologists, pediatricians, pathologists, diagnostic radiologists, and radiotherapists.

Number of speakers and session chairs proposed for potential reimbursement:

Chairs and invited speakers will be provided travel expenses and a per diem for hotel, and meals (amount to be decided). Funds have been budgeted to provide travel grants to scientists and physicians from Central and Eastern European countries so that they may attend this conference.

**CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology**

**Brief description for Continuing Medical Education purposes and for
promotion:**

This conference will address childhood malignancy from the aspects of basic and clinical sciences, attempting to relate the two as possible. This will include the leukemias, central nervous system tumors, and the solid tumors of infancy and childhood. Among the topics considered will be molecular genetics, apoptosis, immunology, epidemiology, bone marrow and stem cell transplantation, clinical pharmacology, long-term survival, screening, ethics, and supportive care. The principal objectives will be to present information to close the gaps between basic and clinical science and between countries with the most advanced treatment modalities and those countries striving to join them.

The first day will be devoted to the hematologic malignancies and solid tumors. Acute leukemia will be addressed in respect to apoptosis, the problem of minimal residual disease, the present status of bone marrow and stem cell transplantation, and current developments in chemotherapy. The epidemiology and treatment of non-Hodgkin's lymphoma will be considered as will the problems of pediatric malignancies in the developing world. The molecular genetic basis of cancer development and specifically that of retinoblastoma will be examined. The second day will be devoted to central nervous system tumors of infants and children. Gliomas will be considered the first half-day and other central nervous system tumors the second half-day. This second day will begin with two talks about the basic science of central nervous system tumors and will survey the common and uncommon neural tumors of childhood. The third day will be concerned with aspects of screening, supportive care, ethics, and long-term survival. The cancer family syndrome and screening for neuroblastoma will be considered. The damaging effects of treatment, particularly the cardiotoxicity of anthracyclines, will be addressed. Finally, the prospects and problems of survival, long-term survival, and ethical issues will be examined. The realities of applying these factors to the practice of pediatric oncology in Central and Eastern Europe will be addressed.

Every professional involved in research related to childhood malignancy and all clinicians treating children should find this conference of interest and use. This will include molecular biologists, immunologists, and geneticists, and clinicians from neurosurgery, neurology, pediatrics (and all of its subspecialties, but especially pediatric hematology and oncology), pathology, neuropathology, diagnostic radiology, and radiotherapy. The multidisciplinary approach to the child with cancer will be presented and stressed. This will include exact anatomic and immunologic diagnosis and staging as well as the

most effective extant treatment protocols. In consideration of the aspirations of the participants from Central and Eastern European countries every attempt will be made to relate the basic and clinical science to the day-to-day practice of those who care for children with cancer.

CONFERENCE TITLE: Challenges and Opportunities in Pediatric Oncology

Scientific rationale for the conference:

Cancer is the second leading cause of death for children in most countries of the Western world. Its impact on mortality and morbidity for children in the rest of the world has received less attention than acute medical problems of infants and children. In the past 30 years, of all of the branches of oncology, the most dramatic and lasting advances have been made in the diagnosis and treatment of cancer of infancy and childhood. It has been established that children cured of cancer (essentially those who survive more than seven years) can expect to have essentially normal lives, that is, quality of life comparable to their siblings and peers. In addition, their survival rates, after cure, closely parallel those of their birth cohorts. Throughout the Western world, research in childhood cancer is being focused on understanding the molecular basis of malignant transformation, improved diagnosis, therapies with increased efficacy and decreased toxicity, and better supportive and follow-up care. Children diagnosed and treated in large centers using carefully designed multidisciplinary protocols have the best survival in respect to quality and length of life. Cure rates in brain tumors, acute lymphocytic leukemia, non-Hodgkin's lymphoma, and Wilms' tumor, for example, in the best centers, now range from 60% to 90%, respectively. The continuing challenge and opportunity in Pediatric Oncology is to increase cure rates and to decrease treatment-related morbidity and mortality.

Crucial to further advances in the diagnosis and treatment of childhood malignancy will be the translation of advances in basic science to clinical strategies. The relation of oncogenes to some heritable cancer syndromes in children is ripe for clinical use. The p53 suppressor oncogene, alone, has proved to be important in several varieties of childhood malignancy. Immunology has considerably sharpened diagnostic specificity in malignant disease, particularly in the acute leukemias of childhood. The first great successes for multi-agent chemotherapy treatment protocols and multi-disciplinary treatment protocols in malignancy were noted in childhood leukemia. Clinical pharmacology, specifically, and the development of treatment protocols, generally, remain at the interface of basic and clinical sciences. This conference will consider all of these issues. There is great opportunity to recognize the special needs of Central and Eastern European countries in the practical application of these general areas.

The best diagnostic and treatment protocols have been developed by large groups of institutions in North America and Europe, such as the Pediatric Oncology Group (POG) and the Societe Internationale d'Oncologie Pediatrique (SIOP). Unfortunately not all children with cancer in the world are diagnosed and treated with these protocols, even in North America

and Europe. The global challenge in Pediatric Oncology is to provide each child with the best treatment available. There is great opportunity now to improve the care of Central and Eastern European children with cancer by reaching and informing scientists and clinicians in these countries. This conference is designed to focus the attention of the best scientists and clinicians in the world of Pediatric Oncology (including Central and Eastern Europe) on Budapest, Hungary, in September 1996, for the Fifth Annual Pediatric Oncology Outreach to Hungary Conference, particularly to reach clinicians and scientists in Albania, Bulgaria, Croatia, the Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia, and Ukraine. The eminence of the speakers and the relevance of their topics guarantee the scientific excellence of this conference. A poster session, will focus on the programs of the Central and Eastern European participants.

Detailed program:

The New York Academy of Sciences

07 - 09 October, 1996

Challenges and Opportunities in Pediatric Oncology

Location: Budapest, Hungary

DATE: 07 October, 1996

7:30-8:30am Registration

8:30-8:45am **Introduction**
Dr. Frederick F. Holmes
University of Kansas Medical Center
Kansas City, Kansas, USA
SESSION I.

Session Title: Molecular Genetics and Transplantation

Session Chair:

György Fekete, M.D., Ph.D.
Second Department of Pediatrics,
Semmelweis University Medical School
Budapest, Hungary

8:45am 1. **Molecular genetic basis of cancer development**
Prof. G. Klein and/or Prof. E. Klein
Karolinska Institute
Stockholm, Sweden

9:20am 2. **The diagnostic and prognostic significance of chromosomal abnormalities in ALL in children**
Eva Oláh, M.D.
Medical University of Debrecen
Debrecen, Hungary

9:55am 3. **Apoptosis and ALL in children**
Dezsö Schuler, M.D., Ph.D., D.Sc, F.R.C.P.
(co-author, Bela Szende, M.D., Ph.D., D.Sc.)
Second Department of Pediatrics,
Semmelweis University Medical School
Budapest, Hungary

10:30-11:00am Intermission

11:00am 4. **The present role of bone marrow and stem cell transplantation in the therapy of leukemic children**
Helmut Gadner, M.D.
St. Anna's Children's Hospital
Vienna, Austria

13

11:35am 5. **Minimal residual disease in leukemia in children**
Bernhardt Kornhuber, M.D.
University Hospital
Frankfurt, Germany

12:05-2:00pm Lunch

SESSION II.

Session Title: Clinical Application of Basic Science Knowledge

Session Chair:

Dezsö Schuler, M.D., Ph.D., F.R.C.P.
Second Department of Pediatrics,
Semmelweis University Medical School
Budapest, Hungary

- 2:00pm 6. **Chemotherapy of acute lymphocytic leukemia, the Pediatric Oncology Group (POG) experience**
William Crist, M.D.
St. Jude's Children's Research Hospital
Memphis, Tennessee, USA
- 2:45pm 7. **The development of chemotherapy in ALL of children**
Hansjörg Riehm
Hannover Medical School
Hannover, Germany
- 3:30pm 8. **The role of clinical pharmacological studies in the development of new treatment strategies**
Joseph Borsi, M.D.
2nd Department of Pediatrics of the
Semmelweis University Medical School
Budapest, Hungary
- 3:30-4:00pm Intermission
- 4:00pm 9. **Chemotherapy of acute myelocytic leukemia in children**
Sverre Lie, M.D.
University Hospital, University of Oslo
Oslo, Norway
- 4:45pm 10. **Epidemiology and treatment of NHL in children**
Ian Magrath, M.D.
National Cancer Institute
Bethesda, Maryland, USA

SESSION III.

Session Title: Gliomas in Infants and Children

Session Chair:

István Nyáry, M.D., Ph.D.
National Institute of Neurosurgery
Budapest, Hungary

- 8:45am 11. **Immunology and biology of gliomas**
Nicolas De Tribolet, M.D.
Hospital Kantonal
Vaudois Lausanne, Switzerland
- 9:20am 12. **Molecular biology of central nervous system tumors**
Rodolf Fahlbusch, M.D.
Freidrich-Alexandre Universitat
Nurnberg, Germany
- 9:55am 13. **Supra and infratentorial gliomas in childhood**
Derek A. Bruce, M.D.
Children's Medical Center
Dallas, Texas, USA
- 10:30-11:00am Intermission
- 11:00am 14. **Optic gliomas**
Robin Humphreys, M.D.
Hospital for Sick Children
Toronto, Ontario, Canada
- 11:35am 15. **Surgery of brain stem tumors**
István Nyáry, M.D., Ph.D.
National Institute of Neurosurgery
Budapest, Hungary
- 12:05-2:00pm Lunch

SESSION IV.

Session Title: Other Tumors of the Central Nervous System

Session Chair:

John J. Kepes, M.D.
University of Kansas Medical Center
Kansas City, Kansas, USA

- 2:00pm 16. **Tumors in the first year of life**
László Bognár, M.D.
National Institute of Neurosurgery
Budapest, Hungary

- 2:45pm 17. **Medulloblastomas**
Maurice Choux, M.D.
Hospital des enfants de la Timone
Marseille, France
- 3:30pm 18. **Adjuvant Chemotherapy of Pediatric Brain Tumors**
Tribhawan S. Vats, M.D.
University of Kansas Medical Center
Kansas City, Kansas, USA
- 3:30-4:00pm Intermission
- 4:00pm 19. **Intraventricular tumors in childhood**
Claude Lapras, M.D.
Hospital Neurologique
Lyon, France
- 4:45pm 20. **Craniopharyngiomas**
János Vajda, M.D.
National Institute of Neurosurgery
Budapest, Hungary

Date: 09 October, 1996

SESSION V.

Session Title: Consequences of Treatment and Screening

Session Chair:

Tribhawan Vats, M.D.
University of Kansas Medical Center
Kansas City, Kansas, USA

- 8:45am 21. **Cancer family syndrome (Fraumeni syndrome)**
Edit Oláh, M.D.
National Institute of Oncology
Budapest, Hungary
- 9:20am 22. **Cardiotoxicity of anthracyclines and its prevention**
Martin Mott, M.D.
Royal Hospital for Sick Children
Bristol, United Kingdom
- 9:55am 23. **Neuropsychologic late effects in pediatric cancer treatment**
Giuseppe Masera, M.D.
Clinica Pediatrica Università di Milano
Monza, Italy
- 10:30-11:00am Intermission

11:00am 24. **The problem of pediatric malignancies in the developing world** Page 4d
Hans Peter Wagner, M.D.
University Hospital, Inselspital
Bern, Switzerland

11:35am 25. **Screening for neuroblastoma**
V.V. Joshi, M.D.
East Carolina University School of Medicine
Greenville, North Carolina

12:05-2:00pm Lunch

SESSION VI.

Session Title: Long-Term Survival, Supportive Care, and Ethical Issues

Session Chair:

Frederick F. Holmes, M.D.
University of Kansas Medical Center
Kansas City, Kansas, USA

2:00pm 26. **Long-term survival in childhood cancer and offspring of childhood cancer survivors**
Grace E. Holmes, M.D.
University of Kansas Medical Center
Kansas City, Kansas, USA

2:45pm 27. **Nutrition and pediatric cancer**
Hedvig Bodanszky, M.D., Ph.D.
Second Department of Pediatrics of the
Semmelweis University Medical School
Budapest, Hungary

3:30pm 28. **Ethical issues in pediatric cancer**
P.A. Voute, M.D.
Emma Children's Hospital
Amsterdam, The Netherlands

3:30-4:00pm **Intermission**

4:00pm 29. **The role of cytokines and supportive therapy in pediatric malignancies**
Thomas Feréncz, M.D.
Second Department of Pediatrics of the
Semmelweis University Medical School
Budapest, Hungary

4:45pm 30. **Infection control in children with cancer**
Csilla Csáki, M.D.
Second Department of Pediatrics of the
Semmelweis University Medical School
Budapest, Hungary

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology

Alphabetical list of the proposed speakers and session chairs:

1. Hedvig Bodanszky, M.D., Ph.D.
Associate Professor, Gastroenterology
Second Department of Pediatrics
Semmelweis University Medical School
Tuzolto u 7-9
1095 Budapest, Hungary
tel: 361-217-2797
FAX: 361-217-2797

2. László Bognár, M.D.
National Institute of Neurosurgery
Amerikai ut 57
1145 Budapest, Hungary
tel: 361-251-2999
FAX: 361-251-5678

3. Joseph Borsi, M.D., Ph.D.
Associate Professor
Chief, Pediatric Oncology and Chemotherapy and Pharmacology
Second Department of Pediatrics
Semmelweis University Medical School
Tuzolto u 7-9
1095 Budapest, Hungary
tel: 361-217-2797
FAX: 361-217-2797

4. Derek A. Bruce, M.D.
Children's Medical Center
1935 Motor St.
Dallas, Texas 75235-7794
USA
tel: 214-640-6660
FAX: 214-640-6308

5. Maurice Choux, M.D.
Hospital des enfants de la Timone
Service de Neurochirurgie Pédiatrique
Cedex 5
Marseille, 13385
France
tel:*****
FAX:*****

6. William Crist, M.D.
St. Jude's Children's Research Hospital
332 N. Lauderdale St.
Memphis, Tennessee 38105-2729
tel: 901-522-0694
FAX: 901-521-9005

7. Csilla Csaki, M.D.
Second Department of Pediatrics
Semmelweis University Medical School
Tuzolto u 7-9
1095 Budapest, Hungary
tel: 361-217-2797
FAX: 361-217-2797
8. Nicolas De Tribolet, M.D.
Hospital Kantonal
Geneva and Hospital University
Faculty of Medicine
Vaudois Lausanne, CH-1011
Switzerland
tel: 021-692-11-11
FAX: 021-692-42-97
9. Rodolf Fahlbusch, M.D.
Freidrich-Alexander Universitat Erlangen-Nürnberg
8520 Erlangen
Schlossplatz 4
Germany
tel: 09131-851
FAX: 09131-852131
10. György Fekete, M.D., Ph.D.
Director, Second Department of Pediatrics
Semmelweis University Medical School
Tuzolto u 7-9
1095 Budapest, Hungary
tel: 361-217-2797
FAX: 361-217-2797
11. Thomas Feréncz, M.D.
Second Department of Pediatrics
Semmelweis University Medical School
Tuzolto u 7-9
1095 Budapest, Hungary
tel: 361-217-2797
FAX: 361-217-2797
12. Helmut Gadner, M.D.
St. Anna's Children's Hospital
Kiderspitalgasse 6
1090 Vienna, Austria
tel: 43-1-401-70250
FAX: 43-1-401-7070

13. Frederick F. Holmes, M.D., F.A.C.P.
Principal Investigator, Pediatric Oncology
Outreach to Hungary
Edward Hashinger Distinguished Professor
University of Kansas Medical Center
Department of Medicine
39th & Rainbow Blvd.
Kansas City, Kansas 66160, USA
Tel: 913-588-4732
FAX: 913-588-4736
14. Grace E. Holmes, M.D.
Professor of Pediatrics and Preventive Medicine
University of Kansas Medical Center
Department of Pediatrics and Preventive Medicine
39th & Rainbow Blvd.
Kansas City, Kansas 66160, USA
Tel: 913-588-4732
FAX: 913-588-4736
15. Robin P. Humphreys, M.D.
Hospital for Sick children
555 University Ave., 1050
Toronto, Ontario M5G 1x8
Canada
tel: 416-813-6427
FAX: 416-813-4975
16. Vijay V. Joshi, M.D.
East Carolina University School of Medicine
Department of Pathology & Laboratory Medicine
Brody Medical Science Bldg.
Rm 1508
Greenville, North Carolina 27858, USA
tel: 919-816-5912
FAX: 919-816-8200
17. John J. Kepes, M.D.
Co-investigator, Pediatric Oncology Outreach to Hungary
Professor Emeritus
University of Kansas Medical Center
Department of Pathology and Laboratory Medicine
39th & Rainbow Blvd.
Kansas City, Kansas 66160, USA
Tel: 913-588-4732
FAX: 913-588-4736
18. E. Klein, M.D.
Department of Immunobiology
Karolinska Institute
S-10401 Stockholm 60
Sweden
tel: 46-8-340-560

19. G. Klein, M.D.
Department of Immunobiology
Karolinska Institute
S-10401 Stockholm 60
Sweden
tel: 46-8-340-560
20. Bernhardt Kornhuber, M.D.
University Hospital
Theodor Stern Kay 7
60590 Frankfurt
Germany
tel: 49-69-630-15-249
FAX: 49-69-630-16700
21. Claude Lapras, M.D.
Hospital Neurologique
50 Bd. Pinel
Lyon, 69394
France
tel:*****
FAX:*****
22. Sverre O. Lie, M.D.
Department of Pediatrics
University Hospital
University of Oslo
POB 1072 Blindern
0316 Oslo, Norway
tel: 02-855-050
FAX: 02-854-442
23. Ian Magrath, M.D.
National Cancer Institute
900 Rockville Pike
Bldg. 10, Rm. 13N240
Bethesda Maryland 20892, USA
tel: 301-496-1544
FAX: 301-402-0575
24. Giuseppe Masera, M.D.
Clinica Pediatrica Universita di Milano
Ospedale Nuovo San Gerardo
Via Doizetti 106
20052 Monza, Italy
tel: 39-39-363-3513
FAX: 39-39-230-1646

25. Martin Mott, M.D.
Royal Hospital for Sick Children
Institute of Child Health
Department of Pediatric Oncology
St. Michael's Hill
Bristol, BS2 8BJ
United Kingdom
tel: 44-272-285-396
FAX: 44-272-285-682

26. István Nyáry, M.D., Ph.D.
Co-investigator, Pediatric Oncology Outreach to Hungary
Director, National Institute of Neurosurgery
Amerikai ut 57
1145 Budapest
Hungary
tel: 361-251-2999
FAX: 361-251-5678

27. Edit Oláh, M.D.
National Institute of Oncology
Ráth György u 7-9
1122 Budapest
Hungary
tel: 36-1-155-0125
FAX: 36-1-156-2402

28. Eva Oláh, M.D.
Medical University of Debrecen
Pediatric Department
Nagyerdei krt. 98
4032 Debrecen
Hungary
tel: 36-52-411-600
FAX: 36-52-414-992

29. Hansjörg Riehm, M.D.
Hannover Medical School
Department of Pediatric Hematology/Oncology
P.O. Box 610180
30623 Hannover, Germany
tel: 49-511-532-6117
FAX: 49-511-532-6029

30. Dezsö Schuler, M.D., Ph.D., F.R.C.P.
Co-Investigator, Pediatric Oncology Outreach to Hungary
Director, National Institute of Pediatrics
President, Hungarian Pediatric Oncology Section
Director Emeritus, 2nd Department of Pediatrics
Semmelweis University Medical School
Tuzolto u 7-9
1095 Budapest, Hungary
tel: 361-217-2797
FAX: 361-217-2797

31. János Vajda, M.D.
National Institute of Neurosurgery
Amerikai ut 57
1145 Burdapest
Hungary
tel: 361-251-2999
FAX: 361-251-5678

32. Tribhawan Vats, M.D.
Co-investigator, Pediatric Oncology Outreach to Hungary
Chief, Pediatric Hematology/Oncology
University of Kansas Medical Center
39th & Rainbow Blvd.
Kansas City, Kansas 66160, USA
tel: 913-588-4732
FAX: 913-588-4736

33. P.A. Voute, M.D.
Emma Children's Hospital
Academic Medical Centre
Department of Pediatric Oncology, Room F8-239
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
tel: 31-20-566-5655
FAX: 31-20-691-2231

34. Hans Peter Wagner, M.D.
University Hospital
Inselspital
Department of Pediatrics
3010 Bern, Switzerland
tel: 41-31-632-9495
FAX: 41-31-632-9748

13

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology

Proposed reviewers:

1. Larry E. Kun, M.D.
University of Texas Health Science Center at San Antonio
Dept. of Pharmacology
7703 Floyd Curl Dr.
San Antonio, Texas 78284-7701
tel: 210-567-8355
FAX: 210-567-8328

2. David G. Poplack, M.D.
Baylor College of Medicine
Department of Pediatrics
Chemotherapy/Oncology
One Baylot Plaza
Houston, Texas 77030
tel: 713-770-4200
FAX: 713-770-4299

3. Teresa J. Vietti, M.D.
Washington University School of Medicine
Children's Hospital
P.O. Box 14871
Saint Louis, Missouri 63178-4871
tel: 314-454-6000
FAX: 314-367-4916

4. Ronald Barr, M.D.
McMaster University Medical Center
Department of Pediatrics
1200 Main Street West
Hamilton Ontario L8N3Z5 Canada
tel: 416-521-2100 X5625
FAX: 416-521-1703

5. Darell D. Bigner, M.D., Ph.D.
Department of Pathology
Box 3156
Duke University Medical Center
Durham, North Carolina 27710
tel: 919-684-5018

6. Peter C. Burger, M.D.
Department of Pathology
Johns Hopkins Hospital
600 N. Wolfe St.
Baltimore, Maryland 21287
tel: 410-955-8378

214

7. Lucy B. Rorke, M.D.
Philadelphia Children's Hospital
Department of Pathology
34th & Civic Ctr., Blvd.
Philadelphia, Pennsylvania 19104
tel: 215-590-1734
FAX: 215-590-1736

8. Bernd W. Scheithauer, M.D.
Mayo Clinic
Department of Pathology and Laboratory Medicine
200 First St. SW
Rochester, Minnesota 55901
tel: 507-284-8350
FAX: 507-284-1599

9. Giulio D'Angio, M.D.
Hospital University of Pennsylvania
Department of Radiotherapy
Donner 2
Philadelphia, Pennsylvania 19104
tel: 215-590-2477
FAX: 215-590-3770

10. Stuart E. Siegel, M.D.
Children's Hospital Los Angeles
Pediatric Oncologist/Hematologist
Division of Hematology/Oncology
4650 Sunset Blvd., #54
Los Angeles, California 90027
tel: 213-669-2205
FAX: 213-660-7128

11. Arthur R. Ablin, M.D.
University of California Medical Center
Pediatric Hematology/Oncology
Box 0106, M647
San Francisco, California 94143
tel: 415-476-3831
FAX: 415-476-4009

12. Mark E. Nesbit, M.D.
University of Minnesota
Pediatric Hematology/Oncology
Box 484
420 Delaware St. SE
Minneapolis, Minnesota 55450
tel: 612-626-2778
FAX: 612-626-2815

15

13. Audrey E. Evans, M.D.
Children's Hospital of Philadelphia
Pediatric Hematology/Oncology
9th flr.
Division of Oncology
34th & Civic Center Blvd.
Philadelphia, Pennsylvania 19104
tel: 215-590-2250
FAX: 215-590-3770

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology

Proposed funding sources

I. U.S. Agency for International Development (USAID)

Pediatric Oncology Outreach to Hungary (POOH) project

\$100,000 for conference expenses

\$100,000 to underwrite East European participant and
attendee expenses

Additional funds may be available through the POOH
grant.

II. Although not solicited as yet, Prof. Dezsö Schuler assures us that
donations from pharmaceutical and medical supply companies would
be forthcoming.

III. Registration fees from West European and US attendees.

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology

Societies, agencies, group interested in hearing about this conference:

1. U.S. Agency for International Development
Partnerships in Healthcare for Eastern Europe
Julia Terry, Project Officer
ENI/HR/HP
Room NS 2669
Department of State
Washington, DC 20523-0053
2. American International Health Alliance
James P. Smith, Executive Director
1212 New York Ave., NW
Suite 825
Washington, DC 20005
tel: 202-789-1136
FAX: 202-789-1277
3. Hungarian Medical Association in America
Alexander Matolcsy, M.D., President
64 Briarwood Ave.
South Bridge, Massachusetts 01550
tel: 508-764-7113
4. International Union Against Cancer
3, Rue Du Conseil-General
1205 Geneva Switzerland
FAX: 4122-3201-18-10
5. American Society of Clinical Oncology (ASCO)
Robert E. Becker, JD, CAE, Executive Director
435 North Michigan Ave.,
Suite 1717,
Chicago, Illinois 60611-4067
tel: 312-644-0828
FAX: 312-644-8557
6. Societe Internationale d'Oncologie Pediatrique
Prof. Jacque Ninane, M.D., Secretary
c/o IMEDEX
Bruistensingel 360
P.O. Box 3283
NL-5203 DG 's HERTOGENBOSCH, Netherlands
tel: 73-429285
FAX: 73-414766

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology

Other scheduled meetings or sessions or meetings that will deal with this or a very similar topic and that may compete with this meeting for interested researchers.

Societe Internationale d'Oncologie Pediatrique (SIOP)
c/o IMEDEX
Bruistensingel 360
PO Box 3283
NL-5203 DG'SHERTOGENBOSCH
Netherlands
Prof. Jacque Ninane, Secretary
tel: 73-429285
FAX: 73-414766

The Societe Internaticnale d'Oncologi Pediatrique (SIOP) annual meeting will be held in Vienna, just three hours from Budapest, on 2 through 5 October, 1996, and will especially address pediatric brain tumors. The juxtaposition of the SIOP meeting with the POOH symposium to be held on 7 though 9 October, 1996, is an unexpected coup.

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology
Co-Chairs Biographical Sketch

Name Frederick F. Holmes, M.D. [REDACTED] [REDACTED]

Position Title Professor of Medicine
Principal Investigator, Pediatric Oncology
Outreach to Hungary
University of Kansas Medical Center

Education

<u>Institution and Location</u>	<u>Degree</u>	<u>Year Conferred</u>	<u>Field of Study</u>	
University of Puget Sound Tacoma, Washington	B.A.	1950-53	Biology	
University of Washington Seattle, Washington	M.D.	1953-57	Medicine	
Chicago Lutheran Theological Seminary, Chicago, Illinois		1958-59	Theology	
London School of Tropical Medicine and Hygiene, London, England		1959	Trop. Med.	
Malayan Government Officer's Chinese School, Kuala Lumpur, Malaysia		1959-60	Chinese	Language

Professional Experience

Internship, University of Kansas Medical Center, Kansas City, Kansas, 1957-58
 Medical Missionary, Lutheran Church Clinic, Menglembu, Perak, Malaysia, 1960-63
 Resident, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, 1963-65
 Fellow in Hematology, University of Kansas Medical Center, Kansas City, Kansas, 1965-66
 Instructor, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, 1966-67
 Staff Physician, Kansas City Veterans Administration Hospital, Kansas City, Missouri, 1966-68
 Assistant Professor, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas 1967-70
 Chief of Medicine, Kilimanjaro Christian Medical Centre, Moshi, Tanzania, East Africa, 1970-72
 Director, Cancer Data Service, University of Kansas Medical Center, Kansas City, Kansas, 1973-94
 Professor, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, 1978-present
 Associate Director, Center on Aging, University of Kansas Medical Center, Kansas City, Kansas, 1981-present
 Edward Hashinger Distinguished Professor, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, 1982-present
 Consultant, Leavenworth Veterans Hospital, Leavenworth, Kansas, 1984-present

Honors and Awards

Edward Hashinger Distinguished Professor Medicine, University of Kansas Medical Center, Kansas City, Kansas, 1982-present
 Oxford University Invited Lecture, Oxford, England, 1983
 President, American Cancer Society, Kansas Division, 1986-88
 National Delegate, American Cancer Society, 1988-present
 Honorary Professor, Henan Medical University, Zhengzhou, Henan, The People's Republic of China, 1989-present

Publications (Selected from a total of 112)

Page 10a

- Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR, Steinhorn SC, Hassinger DD, Austin DF, Bragg K, Holmes GE, Holmes FF, Latourette HB, Weyer PJ, Meigs JW, Teta MJ, Cook JW, Strong LC. Effects of treatment on fertility in long-term survivors of childhood and adolescent cancer. *New England Journal of Medicine* 1987; 317:1315-1321.
- Mulvihill JJ, Myers MH, Connelly RR, Byrne J, Austin DF, Bragg K, Cook JW, Hassinger DD, Holmes FF, Holmes GE, Krauss MR, Latourette HB, Meigs JW, Naughton MD, Steinhorn SC, Strong LC, Teta MJ, Weyer PJ. Cancer in Offspring of long-term survivors of childhood and adolescent cancer. *Lancet* 1987; 2:813-817.
- Holmes GE, Holmes FF: Cigarette smoking among childhood cancer survivors. *American Journal of Diseases of Children* 1988; 142:123-124.
- Teeter MA, Holmes GE, Holmes FF, Baker A. Decisions about marriage and family among survivors of childhood cancer. *Journal of Psychosocial Oncology* 1988; 5:59-68.
- Holmes GE, Baker A, Bovee EC, Mulvihill JJ, Myers MH, Holmes FF. The availability of insurance to long-term survivors of childhood cancer. *Year Book of Pediatrics*, Year Book Medical Publishers Inc., Chicago, 1987; 446-447.
- Holmes GE, Baker A, Holmes FF, Hassanein RS. Insurance experience of childhood cancer survivors. In: Barofsky I, ed. *Work and Illness: The Cancer Patient*. New York: Praeger, 1989; 71-85.
- Byrne J, Mulvihill JJ, Connelly RR, Austin DA, Holmes GE, Holmes FF, Latourette HB, Meigs JW, Strong LC, Myers MH. Reproductive problems and birth defects in survivors of Wilms' tumor and their relatives. *Medical and Pediatric Oncology* 1988; 16:233-240.
- Zahm SH, Blair A, Holmes FF, Boysen CD, Robel RJ, Fraumeni JF. A case-control study of soft tissue sarcoma. *American Journal of Epidemiology* 1989; 130:665-674.
- Byrne J, Fears TR, Steinhorn SC, Mulvihill JJ, Connelly RR, Austin DF, Holmes GE, Holmes FF, Latourette HB, Teta MJ, Strong LC, Myers MH. Marriage and divorce after childhood and adolescent cancer. *Journal of the American Medical Association* 1989; 262:2693-2699.
- Holmes GE, Holmes FF, Baker AB, Hassanein RS. Childhood cancer survivors: attained adult heights, compared with sibling controls. *Clinical Pediatrics* 1990; 29:268-272.
- Zhao GL, Su S, Jin ZH, Holmes FF, Mai K. The estimates for effective sample size and variance of survival rate. *Mathematical Statistics and Applied Probability (China)* 1991; 6:229-238.
- Zhao GL, Holmes FF, Du SJ, Su S, Wang SY, Xiong SS, Mai K. Follow-up studies on 132 cases of cervical cancer in Kansas for 39 years and the assessment of statistical cure. *Cancer (China)* 1991; 10:121-124.
- Holmes F: Clinical evidence for a change in tumor aggressiveness with age. In: Balducci L, ed: *Geriatric Oncology*. Philadelphia: J.B. Lippincott Company, 1992.
- Dedon JF, Courtney DL, Holmes FF. Addison's disease from tuberculosis in a centenarian. *Journal of the American Geriatrics Society* 1992; 40:618-619.
- Jacobs DH, Holmes FF, McFarlane MJ. Meningiomas are not significantly associated with breast cancer. *Archives of Neurology* 1992; 49:753-756.
- Byrne J, Fears TR, Gail MH, Pee D, Connelly R, Austin DF, Holmes GE, Holmes FF, Latourette HB, Meigs JW, Strong LC, Myers MH, Mulvihill JJ. Early menopause in long-term survivors of cancer during adolescence. *American Journal of Obstetrics and Gynecology* 1992; 166:788-793.
- Zahm SH, Weisenburger DD, Cantor KP, Holmes FF, Blair A. The role of the herbicide atrazine in the development of non-Hodgkin's lymphoma: results from three case-referent studies. *Scandinavian Journal of Work, Environment, and Health*, 1993; 19:108-114.
- Silliman RA, Balducci L, Goodwin JS, Holmes FF, Leventhal EA: Breast cancer care in old age: what we know, don't know, and do. *Journal of the National Cancer Institute* 1993; 85:190-199.
- Sorensen JT, Gerald K, Bodensteiner D, Holmes FF. Effect of age on survival in acute leukemia. *Cancer* 1993; 72:1602-1606.

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology
Co-Chairs Biographical Sketch

Name Tribhawan S. Vats, M.D. [REDACTED] [REDACTED]

Position Title Chief, Pediatrics Hematology/Oncology Section
Co-Investigator, Pediatric Oncology Outreach
to Hungary
University of Kansas Medical Center

Education

<u>Institution and Location</u>	<u>Degree</u>	<u>Year Conferred</u>	<u>Field of Study</u>
Ranbir College, Sangur, India	Premed.	1957	Medicine
Government Medical College	M.D.	1963	Gen.Medicine

Professional Experience

Subinternship, Radjendra hospital, Patiala, India, 1963-64
 Medical Officer, Government of India, Ministry of Health, 1964-65
 Internship, Griffin Hospital, Derby, Connecticut, 1965-66
 Pediatric Residency, Maricopa County Hospital, Phoenix, Arizona, 1966-67
 Chief Resident, Pediatrics, Westchester County Hospital, Valhalla, New York, 1967-68
 Chief Resident, Pediatrics, New York Hospital and Cornell Fellowship, Medical College,
 New York, New York, 1968-70
 Fellowship and Instructor, Pediatric Hematology/Oncology, Long Island Jewish
 Hospital, Downstate Medical Center, New York, New York, 1971
 Assistant Professor, Pediatrics, University of Kansas Medical Center, Kansas City,
 Kansas, 1971-76
 Associate Professor, Pediatrics, University of Kansas Medical Center, Kansas City,
 Kansas, 1976-81
 Professor, Pediatrics, University of Kansas Medical Center, Kansas City, Kansas,
 1981-present
 Chief, Pediatric Hematology/Oncology Section, Department of Pediatrics,
 University of Kansas Medical Center, Kansas City, Kansas, 1988-present

Honors and Awards

Principal Investigator, Pediatric Division, Southwest Oncology Group (SWOG), Kansas,
 1975-80
 Principal Investigator, Pediatric Oncology Group (POG), 1981-present
 Member, New Agent and Pharmacology Committee, 1981-present
 Member, Brain Tumor Committee, 1981-present
 Member, Pediatric Hematology/Oncology Discipline Committee, 1981-present
 Member, American Society of Clinical Oncology, 1981-present

Publications

Smith SD, Trueworthy RC, Klopovich RM, Vats TS, Snodgrass W. Management of children
 with isolated testicular leukemia. Cancer 1984; 54:2854-2858.
 Civin C, Krischer P, Land V, Nitschke R, Kamen B, Vats TS. Pediatric Oncology Grant,
 Phase II, Trial of amascarine in children with solid tumors. Cancer Treat. Rep. 1985;
 69(3)335-336.
 Land VJ, Thomas PRM, Boyett JM, Glicksman AS, Culbert S, Castleberry RP, Berry DH, Vats
 T, Hunphrey GB. Comparison of treatment regimens for first central nervous system
 relapse in children with acute lymphocytic leukemia: A Pediatric Oncology Group
 study. Cancer 1985; 56(1):81-87.
 Starling KA, Mulne AF, Vats TS, Schoch I, Dukart G. Mitoxantrone in
 refractory acute leukemia in children: A phase I study. Invest. New Drugs
 1985;3(2):191-195.

- Sexauer CL, Khan A, Burger PC, Krischer JP, Van Eyes J, Vats T, Ragab AH. Cisplatin in recurrent pediatric brain tumors: A POG Phase II study. 1985; 56(7):1497-501. Cancer
- Saving KL, Kimler BF, Vats TS. Intraperitoneal bleomycin for ventriculoperitoneal spread of a hypothalamic astrocytoma. Cancer Drug Deliv. 1986; 3(3):205-210.
- Kimler BF, Martin DF, Evans RG, Morantz RA, Vats TS. Effect of spirogermanium and radiation therapy on the 9L rat brain tumor model. NCI Monographs 1988; 6:115-118.
- Kimler BF, Martin DF, Evans RG, Morantz RA, Vats TS. Combination therapy with intracranial bleomycin and radiation in 9L rat brain tumor model. Int. J. Radiat. Oncol. Biol. Phys. 1990; 18(5):1115-1121.
- Whitehead VM, Bernstein ML, Vega R, Vats TS, Dymont P, Vietti TJ, Krishcher J. Phase I trail of Indicine-N-Oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study. Chemotherapy and Pharmacology 1990; 26:377-379.
- Vats TS, Kamen B, Krischer JP, Camitta B. Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Invest. New Drugs 1991; 9(4):333-7.
- Vats T, Buchanan G, Mehta P, Ragab A, Hvizdala E, Nitschke R, Link M, Beardsley P, Maybee D, Krischer J. Study of Toxicity and Comparative Therapeutic Efficacy of Vindesine-Prednisone vs. Vincristine-Prednisone in Children with Acute Lymphoblastic Leukemia in Relapse. Invest. New Drugs 1992; 10(3): 231-4.
- Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL, Ceftazidime versus Ceftazidime Plus Tobramycin in Febrile Neutropenic Children. Infection 1993; 21(4): 223-8.
- Pappo AS, Vats T, Williams TE, Bernstein M, Kamen BA. Phase I Trial of Trimetrexate in Pediatric Solid Tumors: A Pediatric Oncology Group Study. Medical and Pediatric Oncology 1993; 21(4):280-2.
- Vats TS, Emami A, Smith D. "Oncogenes: Present Status". Indian Journal of Pediatrics 1993; 60:193-201.
- Vats TS, Emami A, Smith D. Bone Marrow Transplantation in Leukemia/Lymphoma. Indian Journal of Pediatrics 1993; 60(4):539-49.
- Advani S, Vats T, Magrath I, et al. Characterization of Acute Lymphoid in Developing Countries: A single institution experience. Leukemia Research (submitted) Leukemia
- Advani S, Vats T, Magrath I, et al. Short Intensified Treatment for Non Hodgkin's Lymphoma in Children. Medical and Pediatric Oncology (submitted)
- Vats TS. Evaluation of response and determination of toxicity of dibromodulcitol (DBD) in children with recurrent solid tumors. Medical and Pediatric Oncology(submitted) Pediatric
- Hardy I, Gershon AA, Steinberg SP, LaRussa P, Vats TS. The incidence of Zoster after immunization with live attenuated varicella vaccine: A study in children with leukemia. New England Journal of Medicine (submitted)
- Vats TS, Krischer J, Harris M, et al. Evaluation of response and further determination of toxicity of dibromodulcitol (DBD) in children with recurrent solid tumors and brain tumors resistant to standard therapy (A POG Phase II Study). Cancer (submitted)
- Vats TS. "Essential Pediatrics" (3rd ed) Chapter on Pediatric Oncology, interpoint 16A narina II, Ghai OP, ed. New Delhi, India, publisher (in press)
- Vats TS. Acute intravascular hemolysis, medical emergencies in children, Dr. Meharban Singh, ed, Interprint 16A Narina II, New Delhi, India, publisher (in press)

33

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology

Co-Chairs Biographical Sketch

Name John J. Kepes, M.D. [REDACTED] [REDACTED]

Position Title Professor Emeritus, Pathology
Co-Investigator, Pediatric Oncology Outreach
to Hungary
University of Kansas Medical Center

Education

<u>Institution and Location</u>	<u>Degree</u>	<u>Year Conferred</u>	<u>Field of Study</u>
University Medical School Budapest, Hungary	M.D.	1952	Neuropathology

Professional Experience

Pathologist-in-Chief, National Institute of Neurosurgery, Budapest, Hungary	1954-56
Fellow in Neuropathology, Mayo Clinic, Rochester, Minnesota, 1957-58	
Rotating Clinical Internship, St. Joseph Hospital, Kansas City, Kansas, 1958-1959	59 City,
Resident-Fellow in Pathology, University of Kansas Medical Center, Kansas City, Kansas, 1959-60	City,
Assistant Professor of Pathology, University of Kansas Medical Center, Kansas City, Kansas, 1960-64	City,
Associate Professor of Pathology, University of Kansas Medical Center, Kansas City, Kansas, 1964-68	City,
Professor of Pathology, University of Kansas Medical Center, Kansas City, Kansas, 1968-1992	
Emeritus Professor of Pathology, University of Kansas Medical Center, Kansas City, Kansas, 1992-present	City,

Honors and Awards

Kansas University Medical Alumni Association, Distinguished Teaching Award, Alpha-Omega-Alpha, Faculty Honor Member, 1976	1972
University of Kansas Medical Center, Medical Student Assembly's Outstanding Award: 1969, 70, 72, 77, 79, 81, 82	Educator
University of Kansas, Chancellor's Teaching Award, 1984	
Kansas University Endowment Association Distinguished Teaching Professorship. recipient of this honor at KU), 1984	(First
Honorary Member, Catalan Academy of Medical Sciences, Barcelona, 1987	
Editorial Advisory Committee: <u>Clinical Neuropathology</u>	
Editorial Board, <u>Journal of Neuropathology and Experimental Neurology</u> , 1984-present	present
Editorial Board, <u>American Journal of Surgical Pathology</u> , 1985-present	

Publications (Selected from a total of 137)

Bernell W, Kepes JJ, Seitz E. Late malignant recurrence of childhood cerebellar astrocytoma. J Neurosurg 1972; 37:470.	
Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: A distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer 1979; 44:1839-1852.	favorable
Kepes Jj. The pathology of brain tumors I-IV, Second ed. Famous teaching in medicine. MEDCOM 1979; New York.	modern
Kepes JJ, Rengachary S, Lee SH. Astrocytes in hemangioblastomas of the nervous system and their relationship to stromal cells. Acta Neuropath 1979; 47:99-104.	central

- Kepes JJ, Lewis RC, Vergara GG. Cerebellar astrocytoma invading the musculature and soft tissue of the neck. *J Neurosurg* 1980; 52:414-418.
- Kepes JJ, Chien WYK, Pang LC, Kepes M. Brain tumors in Taiwan, Republic of China: A statistical study. *Surg Neurol* 1984; 22: 149-156.
- Kepes JJ, Chen WYK, Connors MH, Vogel FS. "Chordoid" meningeal tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the Castleman syndrome. A report of seven cases. *Cancer* 1988; 62:391-406.
- Bejar JM, Kepes JJ, Koller WC. Hemiballism and tremor due to ependymal cyst. *Movement disorders* 1992; 7:370-372.
- Murray R, Morawetz R, Kepes JJ, Gammal TE, LeDoux M. Lyme neuroborreliosis manifesting as an intracranial mass lesion. *Neurosurgery* 1992; 30:769-773.
- Lindboe CF, Cappelen J, Kepes JJ. Pleomorphic xanthoastrocytoma as a component of a cerebellar ganglioglioma: case report. *Neurosurgery* 1992; 31:353-355.
- Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. *Ann Neurol* 1993; 33:18-27.
- Kepes JJ. Recent onset of temporal lobe seizures caused by an unusual intracerebral mass. *Kansas Medicine* 1993; 94:49-50.
- Kepes JJ, Fegley BR. Astrocytoma infiltrating cerebral cortex causing epileptic seizures: A pictorial essay. *J. Epilepsy* 1993; 6:112-114.
- Cerda-Nicolas M, Kepes JJ. Gliofibromas (including malignant forms) and gliosarcomas: a comparative study and review of the literature. *Acta Neuropathol* 1993; 85:349-361.
- Kepes JJ, Chen WYK, Yick FJ. "Mucoid dissolution" of bones and multiple pathologic fractures in a patient with past history of intravenous administration of polyvinylpyrrolidone (PVP): A case report. *Bone and Mineral* 1993; 22:33-41.
- Kepes JJ. Pitfalls and problems in the histopathologic evaluation of stereotactic needle biopsy specimens. *Neurosurgery Clinics of North America* 1994; 5:19-33.
- Kepes JJ, Yarde WL. Renal cell carcinoma followed by a cerebellar mass. *Kansas Medicine* 1994; 95:15-17.
- Selassie L, Rigotti R, Kepes JJ, Towfighi J. Adipose tissue and smooth muscle in a primitive neuroectodermal tumor of the cerebrum. *Acta Neuropathol* 1994; 87:217-222.
- Stechschulte SU, Kepes JJ, Holladay F, McKittrick RJ. Primary meningeal extraosseous Ewing's sarcoma: case report. *Neurosurgery* 1994; 35:143-147.
- McGregor DH, Cherian R, Kepes JJ, Kepes M. Heterotopic brain tissue of middle ear associated with cholesteatoma. *Am J Med Sci* 1994; 308:180-183.
- Kepes JJ. Pleomorphic xanthoastrocytoma: The birth of a diagnosis and a concept. *Brain Pathol* 1993; 3:269-274.
- Kepes JJ. Lipidized meningotheial tumor cells in "xanthomatous" meningioma express macrophage antigen. *J Neuropathol exp Neurol* 1994; 53:384-388.
- O'Boynick P, Green KD, Batnitzky S, Kepes JJ, Pietak R. Aneurysm of the left middle cerebral artery caused by myxoid degeneration of the vessel wall. *Stroke* 1994; 25:2283-2286.
- Kepes Jj, Malone DG, Griffin W, Moral LA, Yarde WL, Jones S. Surgical "touch artefacts" of the cerebral cortex. An experimental study with light and electron microscopic analysis. *Clin Neuropathol* 1995; 14:86-92.

25

**CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology**

Co-Chairs Biographical Sketch

Name Dezső Schuler, M.D., Ph.D., F.R.C.P. [REDACTED] [REDACTED]

Position Title Director, National Institute of Pediatrics,
Budapest, Hungary
President, Hungarian Pediatric Oncology Section
Co-Investigator, Pediatric Oncology Outreach

to Hungary
2nd Department of Pediatrics, Semmelweis
University Medical School, Budapest, Hungary

Education

<u>Institution and Location</u>	<u>Degree</u>	<u>Year Conferred</u>	<u>Field of Study</u>
Semmelweis Medical University Budapest, Hungary	M.D.	1951	Medicine
Semmelweis Medical University	Ph.D.	1972	Pediatrics

Professional Experience

Resident and Assistant, 1st Department of Pathology, Semmelweis Medical University, Budapest, Hungary, 1951-54
Faculty member, 2nd Department of Pediatrics, Semmelweis Medical University, Budapest, Hungary, 1954-76
Director, 2nd Department of Pediatrics, Semmelweis Medical University, Budapest, Hungary, 1976-1994
Director, National Institute of Pediatrics, Budapest, Hungary, 1976-present

Honors and Awards

European Society of Social Paediatrics (member executive committee)
International Society of Pediatric Oncology (Head of East European Section)
European Society of Oncology
Honorary member: Paediatric Society of Austria, British Paediatric Association, German Paediatric Society, Czech Oncologic Society
Fellow of the Royal College of Physicians (London)
Honorary Guest Lectures: National Cancer Institute; Children's Hospital of Philadelphia; Pediatric Postgraduate Course of GFR; Plenary lecturer, International Congress of Pediatrics; European Congress for Social Paediatrics
Editorial Boards: Pediatric Hematology and Oncology, World Pediatrics and Child Care, Pädiacrie and Grenzgebiete, Acta Paediatrica Hungarica, Mediac and Pediatric Oncology

Publications (Selected from a total of 158)

Schuler D, Polcz A, Révész T, Koós R, Bakos M, Gál N. Psychological late effects of leukemia in children and their prevention. Med Ped Oncol 1981; 9:191-194.
Schuler D. Childhood leukemia: therapeutic and experimental approach. Acta Paed Hung. 1981; 22:99-108.
Schuler D, Kardos G, Koós R, Polcz A, Gács G, Révész T. Late effects of therapy in children previously treated for leukemia or malignant tumors. Acta Paed Hung 1983; 24:255-261.
Schuler D, Bakos M, Zsámbor C, Polcz A, Koós R, Kardos G, Révész T. Psychosocial problems in families of a child with cancer. Med Ped Oncology 1985; 13:173-179.
Fink FM, Grümayer ER, Kardos G, Révész T, Gardner H, Schuler D. Aclacinomycin-A in the induction treatment of childhood AML. Onkologie 1986; 9:154-155.
Fink FM, Grümayer ER, Kardos G, Révész T, Gardner H, Schuler D. Aclacinomycin-A in the induction treatment of childhood AML. Haem and Blood Transf 1987; 393-98.

- Borsi JD, Révész T, Schuler D. Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia. *Cancer Chemoth and Pharmacology* 1987; 19:261-264.
- Borsi JD, Schuler D, Moc PJ. Methotrexate during 6 hours and 24 hours: a pharmacokinetic comparison. *Cancer Chemoth and Pharmacology* 1988; 22:33-35.
- Oláh É, Balogh E, Szollár J, Szakmáry É, Kovács I, Schuler D, Karmazsin L. Cytogenetic investigations on children with acute non-lymphocytic leukemia. *Cancer Chemoth and Pharmacology* 1988; 56:249-255. Blut
- Schuler D, Somló P, Borsi J, Paraicz E, Rávasz T, Kardos G, Koós R. New drug combination for the treatment of relapsed brain tumors in children. *Ped Hem Oncology* 1988; 5:153-156. and
- Schuler D, Klinger A. Plötzlicher, unerwarteter Tod in Säuglingsalter am von Ungarn. *Kinderarzt* 1990; 6:915-920. Beispiel
- Schuler D, et al. Neuropsychologic and CT examinations in leukemic patients surviving 10 or more years. *Med Ped Oncol* 1990; 18:123-125.
- Schuler D, Somló P, Koós R, Kálmánchey R, Paraicz E. the treatment of malignant scala posterior brain tumors in children: I. The chemotherapy of relapsed medulloblastoma with a dibromdulcitol-containing drug regime and pharmacokinetic studies of DBD in children. *Med Ped Oncology* 1991
- Schuler D, Somló P, Koós R, Kálmánchey R, Paraicz E. The treatment of malignant scala posterior brain tumors in children: II. Preliminary result of the pre- and postoperative adjuvant chemotherapy of scala posterior tumors. *Med Ped Oncology* 1991
- Schuler D. Pediatric care in Hungary. *Arch Dis Child* 1992; 67:1042-1045.
- Schuler D. Spätfolgen der Tumorbehandlung im Kindesalter unter besonderer Berücksichtigung der Leukämie. *Sozialpädiatrie* 1992; 14:837-840.
- Schuler D, et al. The treatment of malignant scala posterior tumors in children. *Med ped Oncol* 1993; 20:312-314.
- Schuler D, et al. The treatment of malignant scala posterior tumors in children. *Med Ped Oncol* 1993; 21:274-279.
- Schuler D, et al. Support for families of children with malignant disease. *World Pediatrics and Child Care* 1995; 5:43-47. World
- Schuler D, Somló R, Koós R, Kálmánchey R, Paraicz E. The treatment of malignant scala posterior tumors in children: II preliminary result of the pre- and postoperative adjuvant chemotherapy of scala posterior tumors. *Med Ped Oncology* 1993; 21:274-279. scala
- Schuler D, Szende B, Borsi JD, Marton T, Eocsi J, Magyarossi E, Koós R, Csóka M. Apoptosis as a possible way of destruction of lymphoblasts after glucocorticoid treatment of children with acute lymphoblastic leukemia. *Ped Hem Oncol* 1994; 11:641-649. Hem Oncol
- Paál K, Erdélyi-Tóth, É Pap, Csáki C, Ferencz T, Schuler D, Borsi JD. Pharmacokinetic studies on Elobromol in children with brain tumors. *Anti-Cancer Drugs* 1994; 5:539-547. Cancer

CONFERENCE TITLE: Challenges and Opportunities in Pediatric
Oncology
Co-Chairs Biographical Sketch

Name István Nyáry, M.D., Ph.D. [REDACTED] [REDACTED]

Position Title Director, National Institute of Neurosurgery
Budapest, Hungary

Co-Investigator, Pediatric Oncology Outreach
to Hungary

National Institute of Neurosurgery, Budapest,
Hungary

Education

<u>Institution and Location</u>	<u>Degree</u>	<u>Year Conferred</u>	<u>Field of Study</u>
Semmelweis Medical University Budapest, Hungary (summa cum laude)	M.D.	1969	Medicine
Semmelweis Medical University Budapest, Hungary	board exam	1981	Neurosurgery
Semmelweis Medical University Budapest, Hungary	Ph.D.	1992	Neurology

Professional Experience

Research Associate, Semmelweis Medical University, Budapest, Hungary, 1969-1975
NIH Research Fellow, University of Pennsylvania, Cerebrovascular Research Center, Philadelphia, Pennsylvania, 1972-1974.
Resident, National Institute of Neurosurgery, Budapest, Hungary, 1975-1981
Coordinator, NIH, International EC/IC Bypass Cooperative Study, National Institute of Neurosurgery, 1979-1985
Faculty member, National Institute of Neurosurgery, Budapest, Hungary, 1981-present
Director, National Institute of Neurosurgery, Budapest, Hungary, 1992-present

Honors and Awards

Guest lecturer: Semmelweis Medical School German Faculty, 1986-1988
Co-Chair, Liaison Committee, European Association of Neurosurgeons, 1987
Fellowship Recipient, Soros Foundation, Kantonsspital, Zurich, Germany, 1987
Vice President, European Association of Neurosurgeons, 1991
Fogarty Senior Fellowship, Cerebrovascular Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, 1992-1995
Honorary Lecturer: European Courses for Young Neurosurgeons, European Association of Neurosurgeons

Publications

Kuhl DE, Keivish M, Alvi A, Nyáry I, Staum M. Local cerebral blood volume determined by three dimensional reconstruction of radionuclide scan data. Circulation Res 1975; 36:610-619.
Nyáry I, Kuhl DE, Reivich M, Alavi A, Staum MM. Effect on cerebral blood volume of changes in arterial pCO2 and blood pressure. Acta Physiol Acad Sci Hung 1977; 40:331.
Nyáry I, Dóra E, Sándor P, Kovách AGB, Reivich M. Regional cerebral blood flow during hemorrhagic shock in the baboon. Brain blood supply Mchedlishvili GI, Kovách AGB, Nyáry I ed. Akadémiai Kiadó Budapest 1977; 163-173.
Nyáry I, Maklári E, Kovách AGB, Harka I. Local blood flow of the hypothalamus in hemorrhagic hypotension. Acta Physiol Acad Sci Hung 1977; 49:45-56.
Nyáry I, Pásztor E. Reactivity of the cerebral vascular bed to CO2 in patients with head injury. Advances in Neurology Vol 20, Cervós-Navarro et al (eds), Raven Press, New York 1978;517-520.

- Nyáry I, Vajda J, Pásztor E. Clinical experiences with volume-pressure responses. In: Shulman K, Marmarou A, Miller JD, Becker DP (eds): Intracranial Pressure IV, Springer, New York, 1980;116-119.
- Nyáry I, Kordás M, Vajda J. Relationship of CBF and ICP in children presented with intracranial tumors and chronic hydrocephalus. *Monogr Pediat* 1982;15:56-59.
- Nyáry I, Vajda J. Relationship of cerebral blood volume changes and estimated intracranial compliance. In: Ishil S, Nagai H, Brock M (eds): *Intracranial Pressure V*, Springer, New York 1983;316-319.
- EC-IC Bypass Study Group. The international cooperative study of extracranial/intracranial arterial anastomosis (EC-IC Bypass Study): Methodology and entry characteristics. *Stroke* 1985; 16:397-406.
- EC-IC Bypass Study Group. Failure of extracranial/intracranial arterial bypass to reduce the risk of ischemic stroke. *N Engl J Med* 1985; 313:1191-1200.
- Nyáry I, Vajda J. Clinical evidence of compressed lacunar veins causing plateau waves. In: *Intracranial Pressure VI*. Miller JD, Teasdale GM, Rowan JO, Galbraith SL, Mendelow AD, Springer Verlag Berlin Heidelberg, 1986; 142-145.
- Endres M, Nyáry I, Deák GY. Cerebrovascular disease with reference to motor functions. *Int J Rehab Res* 1988; 11:174.
- Nyáry I, Endres M, Vajda J, Deák GY, Béhídi M, Pásztor E. Role of hemispheric lateralization in the postictal evolution of cerebrovascular stroke. *J Cereb Blood Flow Metabol* 1989; 9:S615.
- Nyáry I, Pásztor E. Neurosurgery and the law: the Hungarian pattern. *Surg Neurol* 1990; 33:75-77.
- Endres M, Nyáry I, Béhídi M, Deák BY. Stroke rehabilitation: Method and evaluation. *Int J Rehab Res* 1990; 13:225-236.
- Nyáry I, Vajda J, Endres M, Bordély K, Deák Gy, Szikora I, Pásztor E. Az agyl vazomotor reaktivitás változása ictus cerebrovascularis követően. *Ideggyógyászati Szemle* 199: 43; 317-328.
- Vajda J, Pásztor E, Orosz E, Nyáry I, Juhász J, Horváth M, Czirják S, Futó J. Early surgery for ruptured cerebral aneurysm. *Int Surg* 1990: 75; 123-126.
- Borbély K, Nyáry I, Vajda J, Lázár L, Pásztor E, Scserbakova E. Radionuklid diagnosztika a traumás eredetű liquorterei korformákban. *Ideggyógyászati Szemle* 1991: 44; 52-83.
- Borbély K, Scserbakova E, Czirják S, Vajda J, Nyáry I, Pásztor E. Hydrocephalusok radionuklid diagnosztikája. *Ideggyógyászati Szemle* 1991: 44; 64-78.
- Horváth M, Pásztor E, Nyáry I, Palkovits M, Solyom A, Tárczy M, Lekka N, Csanda E. Cervical sympathetic ganglion autotransplantation to the caudate nucleus in Parkinson's disease. Preliminary report of three cases. In: Brock M, Banerji AK, Sambasivan M (eds): *Modern Neurosurgery 2*, San Jose Process, Trivandrum, 1991: pp 73-80.
- Sándor, Komjáti K, Relvich M, Nyáry I. Major role of nitric oxide in the mediation of regional CO₂ responsiveness of the cerebral and spinal cord vessels of the cat. *J Cereb Blood Flow Metabol* 1994: 14; 49-58.
- Nyáry I, Vajda J, Parócz E, Toth K. Surgery of brain stem tumors. *Clinical Neuroscience/Ideggyógyászati Szemle* 1994: 47; 187-189.
- Vajda J, Nyáry I, Czirják S, Horváth M. Surgery of vertebro-basilar aneurysms re-evaluated. *Clinical Neuroscience/Ideggyógyászati Szemle* 1994: 47; 206-208.
- Komjáti K, Valkel-Harvich M, Toth J, Dallos G, Nyáry I, Sándor P. Endogenous opioid mechanisms in hypothalamic blood flow autoregulation during stepwise hemorrhagic hypotension and angiotensin II induced acute hypertension in cats. In press (*Acta Physiol Scand*)

**Pediatric Oncology Outreach to Hungary (POOH)
Nursing Section, Budapest, Hungary
September 25-29, 1995**

The third of a series of nursing training sessions was held for nurses of every hospital with a nursing component in Budapest, Hungary at Semmelweis University Medical School. The workshops are held with the intent to increase nursing knowledge of pediatric oncology nursing care and to improve nursing follow up of the patients after they leave the primary pediatric oncology center. Twelve nurses from various institutions; two nurses from Semmelweis II, who coordinated the workshop; and I attended the session which was from September 25 thru September 29, 1995.

It was decided by the planning committee and as a result of the second training session that information was needed about documentation, quality assurance, and standards. Also, the nurses were having difficulty in using nursing diagnoses, a way of assessing for and administering supportive care. The director of the local nursing school lectured on nursing standards and expressed the importance of documentation. The following day I lectured about ways documentation could be done in a timely fashion and the basics of quality assurance.

Other topics presented and discussed were very timely and included the following:

- Use of Erythropoietin in Pediatric Oncology
- Pain Relief in Pediatric Oncology
- Role of Leukocyte Filters in Supportive Therapy of Patients with
Cancer
- Nephrotoxicity of Chemotherapy Agents
- Necessary Testing Prior to Bone Marrow Transplant
- Nutrition Needed for Treatment of Children with Malignant
Diseases
- Epidemiology of Malignant Diseases
- The Parent Role During Treatment of the Child with Malignant
Disease

The Importance of a Parent Support Group
Experiences of Home Nursing Care

A major development occurred during the training session. The Association of the Hungarian Pediatric Oncology Nurses was founded. Nurses not currently attending this educational session came especially for the founding meeting. The primary purpose of the organization is to improve nursing care given to the pediatric cancer patient. Professor D. Schuler actively supported the organization founding as did supervisory nursing persons in Hungary. I was made an honorary member.

More written information on nursing standards, nursing diagnosis, documentation, and quality assurance are to be mailed to Budapest. Informational support for the newly found organization will also be given as needed.

Plans are currently being made to present a poster of the nursing component of the POOH project at the Academic International Nursing Congress to be held September 16-18, 1996 in Kansas City, Missouri.

A camp for patients with cancer which integrates them with normal children is in the forming stages. A visit was made to the campground by Dr. Vats, Dr. Schuler, and myself. Information about fund raising for the camp was shared with the coordinators.



Lavonne Ridder, ARNP, CNS

ADDENDUM TO 1995, 3RD QUARTER REPORT

PEDIATRIC ONCOLOGY OUTREACH TO HUNGARY (POOH)

**EUR #0037-G-00-1078-06
QUARTERLY PROGRAM PERFORMANCE REPORT
YEAR 4, 1995
3rd QUARTER**

Participating Institutions:

University of Kansas Medical Center (KUMC)
National Institute of Neurosurgery (NINS)
Second Department of Pediatrics of the Semmelweis University
Medical School (SDP)

Month/Year: September, 1995

Component Description:

Additions to the Implementation Plan:

G. Dr. Béla Kocsis, Chief of Radiation Therapy, National Institute of Oncology, Budapest, Hungary will travel to KUMC to meet with Dr. Richard Evans, Director of Radiation Oncology, KUMC.

Narrative/Justification:

G. Dr. Béla Kocsis, Chief of Radiation Therapy, National Institute of Oncology, Budapest, Hungary visited KUMC from 24-30 September, 1995. Dr. Kocsis conducts all the radiotherapy for pediatric cancer patients in Budapest. While at KUMC Dr. Kocsis met with Dr. Richard Evans, Director of Radiation Oncology. Dr. Kocsis and Dr. Evans discussed radiotherapy of central nervous system tumors in children, problems in immobilization of children during treatment of brain tumors, and management of histiocytosis. Dr. Evans and Dr. Kocsis also planned an on-going collaboration of data of pediatric central nervous system tumors in children. They plan to publish their findings.

Expenditures per Component:

G. Dr. Béla Kocsis	
airfare.	1300.00
hotel/living expense.	<u>577.00</u>
Total.	1877.04

<u>Status:</u>	<u>Complete</u>	<u>Incomplete</u>	<u>In Process</u>
	G		

4/2